These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38441783)

  • 81. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.
    Ross DM; Babon JJ; Tvorogov D; Thomas D
    Haematologica; 2021 May; 106(5):1244-1253. PubMed ID: 33472356
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Low-dose ruxolitinib shows effective in treating myelofibrosis.
    Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
    Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation.
    Laganà A; Passucci M; Pepe S; Scalzulli E; Carmosino I; Costa A; Bisegna ML; Ielo C; Martelli M; Breccia M
    Eur J Haematol; 2024 Jun; 112(6):938-943. PubMed ID: 38332702
    [TBL] [Abstract][Full Text] [Related]  

  • 85. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
    Gerds AT; Yu J; Scherber RM; Paranagama D; Kish JK; Visaria J; Singhal M; Verstovsek S; Pemmaraju N
    Acta Haematol; 2022; 145(4):448-453. PubMed ID: 35008087
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Developmental Therapeutics in Myeloproliferative Neoplasms.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S43-S52. PubMed ID: 28760302
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
    Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
    Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.
    Krauth MT; Burgstaller S; Buxhofer-Ausch V; Gastl G; Geissler K; Keil F; Krippl P; Melchardt T; Petzer A; Rumpold H; Sliwa T; Wöhrer S; Wölfler A; Gisslinger H
    Wien Klin Wochenschr; 2018 Sep; 130(17-18):495-504. PubMed ID: 30043249
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
    Tefferi A; Pardanani A; Gangat N
    Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
    Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
    J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Janus activated kinase inhibition in myelofibrosis.
    Malhotra H
    Indian J Cancer; 2012; 49(3):260-5. PubMed ID: 23238141
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
    Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cytopenic myelofibrosis: prevalence, relevance, and treatment.
    Vachhani P; Verstovsek S; Bose P
    Expert Opin Pharmacother; 2023 Jun; 24(8):901-912. PubMed ID: 37070147
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Does ruxolitinib prolong the survival of patients with myelofibrosis?
    Cervantes F; Pereira A
    Blood; 2017 Feb; 129(7):832-837. PubMed ID: 28031182
    [No Abstract]   [Full Text] [Related]  

  • 96. The role of pacritinib in the management of myelofibrosis.
    Duong VH; Komrokji RS
    Expert Rev Hematol; 2014 Jun; 7(3):325-32. PubMed ID: 24746271
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
    Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
    Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
    Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
    Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
    Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
    Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.